Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969).
The in vitro activity of a new quinolone, T-3262 [A-60969; DL-7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1-, 4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid monohydrate], was compared with those of ciprofloxacin, ofloxacin, ceftazidime, imipenem, and gentamicin. T-3262 inhibited 90% of isolates of the family Enterobacteriaceae at a concentration of less than or equal to 0.25 micrograms/ml. It was two to four times more active than ofloxacin and similarly or slightly less active than ciprofloxacin. Ninety percent of isolates of Pseudomonas aeruginosa were inhibited at 0.5 micrograms/ml. It was 4- to 8-fold more active than ciprofloxacin and 8- to 16-fold more active than ofloxacin against Pseudomonas cepacia and Pseudomonas maltophilia, which were resistant to imipenem and gentamicin. Most Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis isolates were inhibited at concentrations of less than or equal to 0.008 micrograms/ml. The MIC for 90% of the Staphylococcus aureus isolates, including methicillin-resistant S. aureus, was 0.12 micrograms/ml; that for Staphylococcus epidermidis was 0.5 micrograms/ml, as was that for Enterococcus faecalis. It inhibited 90% of Bacteroides fragilis isolates at 2 micrograms/ml, considerably more active than ciprofloxacin and ofloxacin. The frequency of spontaneous point mutational resistance was less than 10(-10) for members of the family Enterobacteriaceae and Pseudomonas spp. Resistant strains could be selected by repeated subculture. Similar to other quinolones, its activity could be affected by culture conditions. T-3262 showed a postantibiotic suppressive effect on Escherichia coli, P. aeruginosa, and S. aureus.
Espinoza
A M
AM
Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York 10032.
Chin
N X
NX
Novelli
A
A
Neu
H C
HC
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002442:Ceftazidime / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D024841:Fluoroquinolones; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D015378:Imipenem; D009287:Naphthyridines / Q000494:pharmacology*; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology; D013845:Thienamycins / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D005839:Gentamicins; D009287:Naphthyridines; D010078:Oxazines; D013845:Thienamycins; D002939:Ciprofloxacin; D015378:Imipenem; D002442:Ceftazidime; D015242:Ofloxacin; C055185:tosufloxacin